Showing 1 - 10 results of 10 for search 'Ole B. Suhr', query time: 0.03s Refine Results
  1. 1
    Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.

    Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition. by Sandra Arvidsson, Björn Pilebro, Per Westermark, Per Lindqvist, Ole B Suhr

    Published 2015-01-01
    Get full text
    Article
  2. 2
    Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles.

    Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles. by Nina Norgren, Urban Hellman, Bo Göran Ericzon, Malin Olsson, Ole B Suhr

    Published 2012-01-01
    Get full text
    Article
  3. 3
    The clinical course after glucocorticoid treatment in patients with inflammatory bowel disease is linked to suppression of the hypothalamic–pituitary–adrenal axis: a retrospective observational study

    The clinical course after glucocorticoid treatment in patients with inflammatory bowel disease is linked to suppression of the hypothalamic–pituitary–adrenal axis: a retrospective... by Aghil Ibrahim, Per Dahlqvist, Tommy Olsson, David Lundgren, Mårten Werner, Ole B. Suhr, Pontus Karling

    Published 2017-11-01
    Get full text
    Article
  4. 4
    Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis.

    Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis. by Intissar Anan, Ole B Suhr, Katarzyna Liszewska, Jorge Mejia Baranda, Björn Pilebro, Jonas Wixner, Elisabet Ihse

    Published 2022-01-01
    Get full text
    Article
  5. 5
    Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).

    Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). by Arnt V Kristen, Mathew S Maurer, Claudio Rapezzi, Rajiv Mundayat, Ole B Suhr, Thibaud Damy, THAOS investigators

    Published 2017-01-01
    Get full text
    Article
  6. 6
    Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis

    Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis by Hedvig Paulsson Rokke, Nima Sadat Gousheh, Per Westermark, Ole B. Suhr, Intissar Anan, Elisabet Ihse, Björn Pilebro, Jonas Wixner

    Published 2020-10-01
    Get full text
    Article
  7. 7
    Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

    Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy by David Adams, Ole B. Suhr, Peter J. Dyck, William J. Litchy, Raina G. Leahy, Jihong Chen, Jared Gollob, Teresa Coelho

    Published 2017-09-01
    Get full text
    Article
  8. 8
    A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells

    A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells by Aubin Michalon, Andreas Hagenbuch, Christian Huy, Evita Varela, Benoit Combaluzier, Thibaud Damy, Ole B. Suhr, Maria J. Saraiva, Christoph Hock, Roger M. Nitsch, Jan Grimm

    Published 2021-05-01
    Get full text
    Article
  9. 9
    A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

    A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis by Teresa Coelho, David Adams, Isabel Conceição, Márcia Waddington-Cruz, Hartmut H. Schmidt, Juan Buades, Josep Campistol, John L. Berk, Michael Polydefkis, Jing Jing Wang, Jihong Chen, Marianne T. Sweetser, Jared Gollob, Ole B. Suhr

    Published 2020-07-01
    Get full text
    Article
  10. 10
    Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner

    Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner by Morie Gertz, David Adams, Yukio Ando, João Melo Beirão, Sabahat Bokhari, Teresa Coelho, Raymond L. Comenzo, Thibaud Damy, Sharmila Dorbala, Brian M. Drachman, Marianna Fontana, Julian D. Gillmore, Martha Grogan, Philip N. Hawkins, Isabelle Lousada, Arnt V. Kristen, Frederick L. Ruberg, Ole B. Suhr, Mathew S. Maurer, Jose Nativi-Nicolau, Candida Cristina Quarta, Claudio Rapezzi, Ronald Witteles, Giampaolo Merlini

    Published 2020-09-01
    Get full text
    Article

Search Tools: